About context therapeutics inc - CNTX
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.
CNTX At a Glance
Context Therapeutics, Inc.
2001 Market Street
Philadelphia, Pennsylvania 19103
| Phone | 1-267-225-7416 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -26,725,104.00 | |
| Sector | Health Technology | Employees | 12 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
CNTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.989 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 1.101 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.007 |
CNTX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,227,092.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
CNTX Liquidity
| Current Ratio | 35.546 |
| Quick Ratio | 35.546 |
| Cash Ratio | 34.358 |
CNTX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -46.808 |
| Return on Equity | -49.889 |
| Return on Total Capital | -27.989 |
| Return on Invested Capital | -49.837 |
CNTX Capital Structure
| Total Debt to Total Equity | 0.23 |
| Total Debt to Total Capital | 0.23 |
| Total Debt to Total Assets | 0.224 |
| Long-Term Debt to Equity | 0.118 |
| Long-Term Debt to Total Capital | 0.117 |